Article

Drug-Drug Interaction Potential of SH-1028, a Third-generation EGFR-TKI: In Vitro and Clinical Trials

2022-11-29

Abstract excerpt

SH-1028 is an irreversible third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI) for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). Considering the possibility of combination therapy in patients with NSCLC, we investigated the drug-drug interaction (DDI) potential of SH-1028 both in vitro and in clinical trials. The in vitro studies were conducted to determine the potentia...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8f9d6874-5c15-52fb-b39c-a543a5c6aac7
DOI: 10.22541/au.166973114.48538191/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Drug-Drug Interaction Potential of SH-1028, a Third-generation EGFR-TKI: In Vitro and Clinical TrialsDOI 10.22541/au.166973114.48538191/v1Read

Drug-Drug Interaction Potential of SH-1028, a Third-generation EGFR-TKI: In Vitro and Clinical TrialsSemantic proximity Read

Development and validation of an LC-MS/MS method for simultaneous determination of SH-1028, an irreversible third-generation EGFR TKI, and two of its metabolites in human plasma: application in clinical pharmacokinetics.Semantic proximity Read

The inhibitory effect of isavuconazole on almonertinib metabolism and its underlying mechanismSemantic proximity Read

[A review: drug-drug interactions of epithelial growth factor receptor-tyrosine kinase inhibitors].Semantic proximity Read

Pharmacokinetics, tissue distribution and identification of putative metabolites of JI-101 - a novel triple kinase inhibitor in rats.Semantic proximity Read

Evaluation of the pharmacokinetic effects of itraconazole on alflutinib (AST2818): an open-label, single-center, single-sequence, two-period randomized study in healthy volunteers.Semantic proximity Read

Therapeutic effects and adverse drug reactions are affected by icotinib exposure and CYP2C19 and EGFR genotypes in Chinese non-small cell lung cancer patients.Semantic proximity Read

Pharmacokinetic Drug-Drug Interactions of DA-8010 with Clarithromycin or Rifampicin: Influence of CYP2D6 Phenotype on the Extent of These Interactions.Semantic proximity Read

Drug–drug interactions with pioglitazone, losartan, and midazolam and anti-tumor efficacy and safety study of TAS- 115 in patients with solid tumorsSemantic proximity Read

Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers.Semantic proximity Read

Unexpected Effect of Rifampin on the Pharmacokinetics of Linezolid: In Silico and In Vitro Approaches to Explain Its MechanismSemantic proximity Read

Population Pharmacokinetics and Adverse Events of Erlotinib in Japanese Patients with Non-small-cell Lung Cancer: Impact of Genetic Polymorphisms in Metabolizing Enzymes and Transporters.Semantic proximity Read